Aspergillus valve endocarditis in patients without prior cardiac surgery

• Published in: Medicine (Baltimore) 2000-07, Vol.79 (4), p.261-268
• Main Authors: Gumbo, T, Taege, A J, Mawhorter, S, McHenry, M C, Lytle, B H, Cosgrove, D M, Gordon, S M
• Format: Article
• Language: English
• Subjects: Aged; Amphotericin B - therapeutic use; Antifungal Agents - therapeutic use; Aspergillosis - diagnosis; Aspergillosis - drug therapy; Aspergillosis - physiopathology; Diagnosis, Differential; Endocarditis, Bacterial - diagnosis; Endocarditis, Bacterial - drug therapy; Endocarditis, Bacterial - physiopathology; Female; Heart Valves - microbiology; Heart Valves - pathology; Humans; Immunocompromised Host; Male; Middle Aged; Prognosis
• ISSN: 0025-7974
• DOI: 10.1097/00005792-200007000-00007

Aspergillus native valve endocarditis in patients who have not had cardiac surgery is uncommon. We report 3 cases and review 58 other adult patients reported in the English-language literature. Sixty-seven percent of the patients had underlying immunosuppression. The clinical features were fever (74%), embolic episodes (69%), a new or changing heart murmur (41%), and sudden visual loss (13%). Patients with mural endocarditis were more often immunosuppressed, especially due to solid organ transplants, but had lower frequency of heart murmurs and embolic episodes. Echocardiography revealed a vegetation in 78% of all the cases in which it was performed. Examination and culture of biopsy material often helped to establish a diagnosis of Aspergillus infection. Twenty-five patients had an antemortem diagnosis. These patients received a mean cumulative amphotericin B dose of 27 mg/kg. Twenty percent (3/15) of patients who received combined surgical and medical therapy survived, compared to none of those who received medical therapy alone (p = 0.08). Patients who survived were not immunosuppressed. We conclude that native valve aspergillus infective endocarditis is uniformly fatal without surgical intervention and antifungal therapy.